2. April 2016 von

Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Placebo In Adults With Type 2 Diabetes

Novo Nordisk A/S: Boston (ots/PRNewswire) – For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #OR15-1 Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like …

Das könnte Sie interessieren

  1. Victoza® (liraglutide 1.8 mg) Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment

Comments are closed.